Progesterone and Progestins

Selected References – Progesterone and progestins:

- Abu-Zaid A, et al. 2025. Cervical pessary versus vaginal progesterone to prevent preterm birth in women with a singleton pregnancy and a short cervix: a systematic review and meta-analysis. Reprod Sci, 32(8):2540-2557.
- American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics. 2021. Prediction and prevention of spontaneous preterm birth: ACOG Practice Bulletin, Number 234. Obstet Gynecol, 138(2):e65-e90.
- Bidabadi E, et al. 2026. The association between maternal progesterone use during pregnancy and offspring attention deficit hyperactivity disorder risk. J Atten Disord, 30(3):292-299.
- Carmichael SL, et.al. 2005. Maternal progestin intake and risk of hypospadias. Archives of Pediatrics & Adolescent Medicine, 159(10):957-962.
- Check JH, et al. 1986. The risk of fetal anomalies as a result of progesterone therapy during pregnancy. Fertil Steril, 45:575-577.
- Committee on Drugs. 2001. The transfer of drugs and other chemicals into human milk. Pediatrics, 108(3):776-789.
- Danielsson BR, Ritchie HE. 2025. Review: hormone pregnancy tests were teratogenic by the same failed abortion and hypoxia-related mechanism as misoprostol. Birth Defects Res, 117(3):e2462.
- Devall AJ, et al. 2021. Progestogens for preventing miscarriage: a network meta-analysis. Cochrane Database Sys Rev, 4(4):CD013792.
- Dominsky O, et al. 2026. Vaginal progesterone and the risk of preterm birth in patients with short cervix beyond 24 weeks. Int J Gynaecol Obstet, 172(2):1039-1046.
- Duds I, et al. 2006. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Congenit Anom (Kyoto), 46:194-198.
- Elenis E, et al. 2025. Perinatal outcomes of progesterone in natural frozen-thawed embryo transfer pregnancies: insights from 2 randomized controlled trials. Fertil Steril, 124(1):104-112.
- Eshraghi N, et al. 2025. Combined vaginal progesterone and cervical pessary effect on preterm birth in singleton pregnancies with short cervix: a retrospective cohort study. BMC Pregnancy Childbirth, 25(1):1055.
- Fawzy M, et al. 2008. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet, 278(1):33-38.
- Fernandes Dias M, et al. 2026. Progesterone in pregnancy and neonatal outcomes: a systematic review and meta-analysis of randomized controlled trials. Int J Gynaecol Obstet, 172(2):685-696.
- He YTN, et al. 2025. Cervical cerclage versus cervical pessary with or without vaginal progesterone for preterm birth prevention in twin pregnancies and a short cervix: a two-by-two factorial randomised clinical trial. PLoS Med, 22(2):e1004526.
- Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy. Littleton, Mass.: John Wright-PSG, pp 389, 391-392, 394, 443, 478, 497.
- Heinonen OP, et al. 1977. Cardiovascular birth defects and antenatal exposure to female sex hormones. N Engl J Med, 296:67-60.
- Kanbak AR, Öztekin DC. 2025. Is the use of vaginal progesterone a factor in pregnant women diagnosed with gestational diabetes mellitus? Rev Assoc Med Bras (1992), 71(8):e20250444.
- Lokshin VN, et al. 2024. Progestin-primed ovarian stimulation outcomes in in-vitro fertilization (IVF) – a systematic review of the literature. Gynecol Endocrinol, 40(1):2414783.
- Massai R, et al. 2005. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. Contraception, 72:352-357.
- Mei Y, et al. 2025. Impact of the PPOS protocol on euploidy embryo rates and reproductive outcomes in preimplantation genetic testing cycles: a systematic review. Front Endocrinol (Lausanne), 16:1595232.

- Michaelis J, et al. 1983. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology, 27:57-64.
- Nachum Z, et al. 2024. Vaginal progesterone for pregnancy prolongation after arrested preterm labor: a randomized clinical trial. JAMA Netw Open, 7(7):e2419894.
- Nguyen HTL, et al. 2025. Intensive luteal phase support in hormone replacement and modified natural cycle frozen embryo transfers in ovulatory patients: a propensity score-matched study. PLoS One, 20(7):e0327470.
- Norman JE, et al. 2009. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet, 373(9680):2034-2040.
- Practice Committee of the American Society for Reproductive Medicine. 2008. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertility and Sterility, 89(4):789-792.
- Practice Committee of the American Society for Reproductive Medicine. 2012. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertility and Sterility, 98(5):1103-1111.
- RamaRao S, et al. 2013. Progesterone vaginal ring: introducing a contraceptive to meet the needs of breastfeeding women. Contraception, 88(5):591-598.
- Rinaldi L, et al. 2024. Oral dydrogesterone along with vaginal micronized progesterone supplementation for luteal phase support in IVF patients, and its impact on pregnancy and live birth rates: a prospective randomized trial. BMC Pregnancy Childbirth, 24(1):845.
- Roy M, et al. 2020. Progesterone vaginal ring as a new contraceptive option for lactating mothers: evidence from a multicenter non-randomized comparative clinical trial in India. Contraception, 102(3):159-167.
- Silver RI, et al. 1999. In vitro fertilization is associated with an increased risk of hypospadias. J Urology, 161(6):1954-1957.
- Ti A, et al. 2025. Progestogen-only contraception use during breastfeeding: an updated systematic review. BMJ Sex Reprod Health, 51(Suppl 1):s4-s17.
- Wang X, et al. 2024. The effectiveness of vaginal progesterone to prevent preterm birth in singleton pregnant women with a short cervix at 18-32 weeks gestation. J Matern Fetal Neonatal Med, 37(1):2412751.
- Wu HM, et al. 2025. Smooth endoplasmic reticulum aggregates in oocytes: a comparison of progestin-primed and GnRH antagonist IVF protocols. J Ovarian Res, 18(1):181.
- Wu JN, et al. 2025. Association of combined folic acid and progesterone use with congenital malformations in women with vaginal bleeding during early pregnancy: a multicenter cohort study. Eur J Med Res, 30(1):1057.
- Xie YX, et al. 2025. Comparison of oral dydrogesterone and vaginal progesterone for luteal phase support in natural and modified natural cycle frozen embryo transfers. J Ovarian Res, 18(1):183.
- Yu L, et al. 2024. Evaluation of two luteal support regimens, intramuscular progesterone and progesterone vaginal gel, for vitrified-warmed embryo transfer in women with chronic salpingitis: a single-center 8-year retrospective study. Eur J Med Res, 29(1):619.
- Zhang W, et al. 2025. No improvement in pregnancy and perinatal outcomes with combined luteal support in modified natural cycle frozen embryo transfer. Front Endocrinol (Lausanne), 15:1458527.
- Zhao H, et al. 2025. Efficacy and safety of different progestogens in women with first threatened miscarriage: a network meta-analysis. Int J Gynaecol Obstet, 168(3):944-957.
- Zhao J, et al. 2025. Cesarean delivery modifies the association between prenatal exogenous progesterone and cryptorchidism: a case-control study. Eur J Pediatr, 184(12):746.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Progesterone and Progestins

Selected References:

- Asghar FA, et al. 2024. LTRA use in pregnancy: a systematic review on their safety and association with congenital anomalies'. JRGM, 13(2):1-8.
- Committee on Drugs. American Academy of Pediatrics. 2001. The transfer of drugs and other chemicals into human milk. Pediatrics. 108:776-789.
- Cossette B, et al. 2014. Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. Ann Allergy Asthma Immunol. 112(5):459-464.
- Eltonsy S, et al. 2011. Beta2-agonists use during pregnancy and the risk of congenital malformations. Birth Defects Research Clin Mol Teratol. 91(11):937-947.
- Gregersen TL, Ulrik CS. 2013. Safety of bronchodilators and corticosteroids for asthma during pregnancy: what we know and what we need to do better. J Asthma Allergy. 6:117-125.
- Lim A, et al. 2013. Asthma drugs in pregnancy and lactation. Aust Prescr. 36(5):150–153.
- Lim A, et al. 2011. Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann Pharmacother. 45(7-8):931-945.
- Namazy J, Schatz M. 2018. Management of asthma during pregnancy: optimizing outcomes and minimizing risk. Semin Respir Crit Care Med. 39(01):29-35.
- National Asthma Education and Prevention Program. Working Group. 2004. Report on managing asthma during pregnancy: Recommendations for pharmacologic treatment. Update 2004. NIH publication NO.05-5236. Bethesda, MD: US Department of Health and Human Services; National Institutes of Health; National Heart, Lung and Blood Institute.
- Peterka M, ET AL. 2021. Anti-asthma Drugs Formoterol and Budesonide (Symbicort) Induce Orofacial Clefts, Gastroschisis and Heart Septum Defects in an In Vivo Model. In Vivo. 35(3):1451-1460.
- Tamasi L, et al. 2005. The management of bronchial asthma during pregnancy – Hungarian experiences. [Article in Hungarian] Orv Hetil. 146(45):2035-2039.
- Wilton LV, Shakir SA. 2002. A post-marketing surveillance study of formoterol (Foradil). Its use in general practice in England. Drug Saf. 25:213-223.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Progesterone and Progestins

Selected References:

- Aase JM, et al. 1970. Children of mothers who took LSD in pregnancy. Lancet; 1:100-1.
- Alexander GJ, et al. 1970. Lysergic acid diethylamide intake in pregnancy: fetal damage in rats. J Pharmacol Exp Ther; 173(1):48-59.
- Baquiran M, et al. 2023. Lysergic acid diethylamide toxicity. [Updated 2023 Dec 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553216/
- Cohen MM, et al. 1968. The effect of LSD-25 on the chromosomes of children exposed in utero. Pediat Res 2:486-492.
- Das, Saibal et al. 2016. Lysergic acid diethylamide: a drug of 'use'?. Therapeutic advances in psychopharmacology; 6(3):214-28.
- Fabro S, Sieber SM. 1968. Is lysergide a teratogen? Lancet 1(7543):639.
- Fuentes Jet al. 2020. Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. Frontiers in Psychiatry; 10.943.
- Jacobson CB, Berlin CM. 1972. Possible reproductive detriment in LSD users. JAMA 222(11):1367-1373.
- Haden, M, & Woods, B. 2020. LSD overdoses: three case reports. Journal of Studies on Alcohol and Drugs; 81(1), 115-118.
- Long SY. 1972. Does LSD induce chromosomal damage and malformations? A review of the literature. Teratology; 6(1):75-90.
- McElhatton PR. 2000. Fetal effects of substances of abuse. J Toxicol Clin Toxicol; 38:194-5.
- McGlothlin WH, et al.1970. Effect of LSD on human pregnancy. JAMA.1; 212(9):1483-7.
- Mueller, B. A., Daling, J. R., Weiss, N. S., & Moore, D. E. (1990). Recreational drug use and the risk of primary infertility. Epidemiology (Cambridge, Mass.), *1*(3), 195–200.
- Papac DI and Foltz RL. 1990. Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. J Anal Toxicol; 14(3):189-90.
- Robinson JT, et al. 1974. Chromosome aberrations and LSD. A controlled study in 50 psychiatric patients. J Psychiatry. 125(0):238-44.
- Zellweger H, et al. 1967. Is lysergic-acid diethylamide a teratogen? Lancet; 2(7525):1066-1068.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Progesterone and Progestins

Selected References:

- Alwan S, et al. 2016. Safety of selective serotonin reuptake inhibitors in pregnancy: a review of current evidence. CNS Drugs, 30(6):499-515.
- Andersen JT, et al. 2014. Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage. Obstet Gynecol, 124:655-661.
- Bandoli G, et al. 2020. Prenatal antidepressant use and risk of adverse neonatal outcomes. Pediatrics, 146(1):e20192493.
- Berard A, et al. 2017. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open, 7:e013372.
- Bonari L, et al. 2004. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry, 49(11):726-735.
- Burch KJ and Wells BG. 1992. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics, 89:676-677.
- Chambers CD, et al. 1999. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics, 104(5):I1-15.
- Chambers C, et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med, 354(6)579-587.
- Desaunay P, Eude LG, Dreyfus M, Alexandre C, Fedrizzi S, Alexandre J, Uguz F, Guénolé F. Benefits and Risks of Antidepressant Drugs During Pregnancy: A Systematic Review of Meta-analyses. Paediatr Drugs. 2023 May;25(3):247-265. doi: 10.1007/s40272-023-00561-2. Epub 2023 Feb 28. PMID: 36853497.
- Diav-Citrin O, et al. 2008. Paroxetine and fluoxetine in pregnancy: a prospective, multicenter, controlled, observational study. Br J Clin Pharmacol, 66(5):695-705.
- Gao SY, et al. 2017. Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies. Br J Clin Pharmacol, 83(10):2134-2147.
- Goldstein DJ, Marvel DE. 1993. Psychotropic medications during pregnancy: risk to the fetus. JAMA, 270:2177.
- Goldstein DJ, et al. 1997. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol, 89:713-8.
- Grigoriadis S, et al. 2013. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry, 74(4):e309-20.
- Grigoriadis S, et al. 2019. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis. J Clin Psychiatry, 80(4):18r12412.
- Huybrechts KF, et al. 2014. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med, 370:2397-2407.
- Huybrechts KF, et al. 2015. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension

of the newborn. JAMA, 313(21):2142-2151.

- Isenberg KE. 1990. Excretion of fluoxetine in human breast milk. J Clin Psychiatry, 51:169.
- Jimenez-Solem E et al. 2012. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ, 2:e001148.
- Jordan S, et al. 2019. Antidepressant prescriptions, discontinuation, depression, and perinatal outcomes, including breastfeeding: a population cohort analysis. PLoS One, 14(11):e0225133.
- Kaplan et al. 2017. Maternal SSRI discontinuation, use, psychiatric disorder and the risk of autism in children: a meta-analysis of cohort studies. Br J Clin Pharmacol, 83(12):2798-2806.
- Kieviet N, et al. 2015. Risk factors for poor neonatal adaptation after exposure to antidepressants in utero. Acta Paediatr, 104(4):384-391.
- Kristensen JH, et al. 1999. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol, 48(4):521-527.
- Levinson-Castiel R, et al. 2006. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med, 160:173-176.
- Louik C, et al, 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med, 356:2675-2683.
- Lusskin SI, et al. 2018. Pharmacotherapy for Perinatal Depression. Clin Obstet Gynecol, 61(3):544-561.
- Masarwa R, et al. 2019. Prenatal exposure to selective serotonin reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. Am J Obstet Gynecol, 220(1):57.e1-57.e13.
- Morris R, Matthes J. 2015. Serotonin syndrome in a breast-fed neonate. BMJ Case Rep, doi:10.1136/bcr-2015-209418.
- Moses-Kolko, E.L. et al. 2005. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. Literature review and implications for clinical applications. J Am Med Assoc, 293: 2372-2383.
- Nulman I, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. NEJM, 336(4):258-262.
- Nulman I, et al. 2002. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry, 159(11):1889-1895.
- Ornoy A. 2017. Neurobehavioral risks of SSRIs in pregnancy: Comparing human and animal data. Reprod Toxicol, 72:191-200.
- PD-Rx Pharmaceuticals, Inc. 2025. *Fluoxetine capsules: Prescribing information*. DailyMed. [Accessed August 2026]. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d26f7450-7650-43df-a63b-1fe2472882a9&type=display
- Pedersen LH, et al. 2009. Selective serotonin inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ, 339:b3569.
- Rampono J, et al. 2009. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry, 42(3):95-100.
- Ruchkin V, Martin A. 2005. SSRIs and the developing brain. Lancet, 365:451-453.
- Sanz E, et al. 2005. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet, 365:482-487.
- Sjaarda LS et al. 2020. Urinary selective serotonin reuptake inhibitors across critical windows of pregnancy establishment: a prospective cohort study of fecundability and pregnancy loss. Fertil Steril, 114(6):1278-1287.
- Strain, SL. 1994. Fluoxetine-initiated ovulatory cycles in two clomiphene-resistant women. J Am J Psychiatry, 151(4):620.
- Salisbury AL, et al. 2016. The roles of maternal depression, serotonin reuptake inhibitor treatment, and concomitant benzodiazepine use on infant neurobehavioral functioning over the first postnatal month. Am J Psychiatry, 173(2):147-157.
- Sylvester C, et al. 2019. selective serotonin reuptake inhibitors and fertility: considerations for couples trying to

conceive. Harv Rev Psychiatry, 27(2):108-118.

- Taddio A, Ito S, and Koren G. 1996. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breastmilk. J Clin Pharmacol, 36(1)42-47.
- Vaidya R, et al. 2024. Non epileptiform abnormal neurologic signs in newborns following in-utero psychotropic medication exposure. Journal of Neonatal-Perinatal Medicine. 17(5):717-722.
- Wang S, et al. 2015. Selective serotonin reuptake inhibitors (SSRIs) and the risk of congenital heart defects: a meta-analysis of prospective cohort studies. Journal of the American Heart Association, 4(5)e001681.
- Wen SW, et al. 2006. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol, 194(4):961-966.
- Wisner KL, Avram MJ, George AL Jr, Abramova TV, Yang A, Caritis SN, Costantine MM, Stika CS. Concentrations of Fluoxetine Enantiomers Decline During Pregnancy and Increase After Birth. J Clin Psychopharmacol. 2024 Mar-Apr 01;44(2):100-106.
- Yang F, et al. 2017. Risk of autism spectrum disorder in offspring following paternal use of selective serotonin reuptake inhibitors before conception: a population-based cohort study. BMJ Open, 7(12):e016368.
- Yang F, et al. 2018. Prenatal paternal selective serotonin reuptake inhibitors use and risk of ADHD in offspring. Pediatrics, 141(1):e20171081.
- Yonkers KA, et al. 2009. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol, 114(3):703-713.
- Yoshida, K, et al. 1998. Fluoxetine in breastmilk and developmental outcome of breastfed infants. Br J Psychiatry, 172:175-178. Pregnant Women with Suspected or Confirmed Influenza. Obstet Gyn, 132(4):e169-e173.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Progesterone and Progestins

Selected References:

- Akbari M, et al. 2013. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis, 19(1):15-22.
- Alami Z, et al. 2018. Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study. Therapie, 73(3):199-207.
- Alshwairikh LA, Zeneb B. 2022. A 25-year-old Saudi woman with a 2-year history of antisynthetase syndrome with interstitial lung disease who commenced azathioprine treatment in the third trimester of pregnancy and had a successful birth at term. Am J Case Rep, 7:23:e936833.
- Balevic S, et al. 2024. Azathioprine metabolite levels and outcomes during pregnancies with rheumatic disease. Lupus Sci Med, 11(1):e0011036.
- Casanova MJ, et al. 2013. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol, 108(3):433-440.
- Christensen LA, et al. 2008. Azathioprine treatment during lactation. Aliment Pharmacol Ther, 28(10):1209-1213.
- Davison JM et al. 1985. Maternal azathioprine therapy and depressed haematopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol, 92:233-239.
- de Meij TG, et al. 2013. Dutch Initiative on crohn and colitis. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther, 38(1):38-43.
- Dejaco C, et al. 2001. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology, 121:1048-53.
- Francella A, et al. 2003. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology, 124(1):9-17.
- Friedman S, et al. 2017. Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring: a nationwide cohort study. Reproductive Toxicology, 73:196-200.
- Götestam Skorpen C, et al. 2016. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis, 75(5):795-810.
- Goldstein LH, et al. 2007. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol, 79(10):696-701.
- Hoeltzenbein M, et al. 2012. Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine. Reprod Toxicol, 34(3):364-369.
- Ikram N, at al. 2021. Breastfeeding in women with rheumatic diseases. Lupus Sci Med, 8(1):e000491.
- Khedr L, Ekram M. 2024. Eur J Case Rep Intern Med, 11(4):004385.
- Kinnucan J, Kane S. 2021. Editorial: thiopurines but not anti-TNF monotherapy are linked to worse pregnancy outcomes in a large population-based study. Aliment Pharmacol Ther, 54(3):343-344.
- Langagergaard V, et al. 2007. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther, 25(1):73-81.
- Matalon ST, et al. 2004. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol, 18(2):219-230.
- Matarazzo L, et al. 2021. Pregnancy outcome in women with childhood onset autoimmune hepatitis and autoimmune sclerosing cholangitis on long-term immunosuppressive treatment. Eur J Obstet Gynecol Reprod Biol, 268:7-11.
- Moretti ME et al. 2006. Breast-feeding during maternal use of azathioprine. Ann Pharmacother,

40(12):2269-2272.

- Motta M, et al. 2007. Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents. Am J Perinatol, 24(8):441-447.
- Myer A, et al. 2021. Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018. Aliment Pharmacol Ther, 54(3):302-311.
- Nørgård B, et al. 2004. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther, 19(6):679-685.
- Reynolds JA, et al. 2023. Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology (Oxford), 62(3):1124-1135.
- Skejo C, et al. 2024. Early onset sepsis and lobar pneumonia in a newborn exposed in utero to Ustekinumab and azathioprine. Inflamm Bowel Dis, 30(2):314-315.
- Wolf MF, et al. 2023. Azathioprine and 6-mercaptopurine-induced intrahepatic cholestasis of pregnancy: case report and review of literature: Taiwan J Obstet Gynecol, 63(5):761-764.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.